-The Business Standard Patient safety & Quality our guidance now, says Sawhney Trouble-hit Ranbaxy Laboratories has introduced a whistle-blower policy within the company to encourage transparency and address concerns internally, so that bigger problems could be averted. In his first interaction with the media (the first part of which was published on Sunday) since the drug maker pleaded guilty of making fraudulent statements to the US Food and Drugs Administration (FDA) under its...
More »SEARCH RESULT
Total Matching Records found : 3901
Dinesh Thakur, an ex-Ranbaxy employee who blew the whistle on the company, interviewed by The Economic Times
-The Economic Times Indian pharmaceutical company Ranbaxy recently paid $500 million to the US government to settle civil and criminal charges for making fraudulent statements to the US FDA and selling adulterated drugs in the US. Dinesh Thakur, an ex-Ranbaxy employee who blew the whistle on the company, talks to ET about the five-year long investigation and the future of generic drug companies in the US. Edited Excerpts: * You think you...
More »India has a problem with ineQuality, and it won't be solved easily-Kunal Kumar Kundu
-The Business Standard Why government policy and jobless growth have let ineQuality worsen in recent times The Forbes list of billionaires features 55 Indians in 2013. The estimated net worth of only the top ten is $102.1 billion or approximately 5.5 per cent of India's gross domestic product. Paradoxically, every third poor person and every second malnourished child in the world is also an Indian. India also adds 7.5 million babies with...
More »Ranbaxy case may take a toll on other Indian drug makers
-The Business Standard The tussle between the US Food and Drug Administration (US FDA) and Ranbaxy is likely to hit the plans of Indian pharmaceutical companies of making it big in the US generic drugs market. Apart from the fact that their image may take a beating, the additional scrutiny on abbreviated new drug applications (ANDAs) from India would lead to more delays in drug approvals. Last week, Ranbaxy had agreed to...
More »Privatising the ICDS?-Jayati Ghosh
-Frontline The Central government's proposal to hand over the supply of supplementary nutrition to NGOs in the name of "community participation" is surely an invitation for private profiteering on the back of this supposedly public scheme. ENSURING safe and healthy conditions for the reproduction of the population is obviously the most fundamental requirement of any society. So the progress of a society can be determined (and indeed is routinely judged) by the...
More »
